

Advanced Enzyme Technologies Ltd.

CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India

Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: info@advancedenzymes.com, www.advancedenzymes.com

May 29, 2017

To,

The Listing Department,
BSE Limited
Department of Corporate Affaris
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai- 400 001
Scrip ID-540025

The Listing Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai- 400 051
Scrip Code-ADVENZYMES

Dear Sir/Madam,

Subject: Newspaper publication of Extract of Consolidated Audited Financial Results for the year ended March 31, 2017 alongwith fourth quarter

Ref: ISIN: INE837H01020

Pursuant to provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed copy of the newspaper publication of 'Extract of Consolidated Audited Financial Results for the quarter and year ended March 31, 2017' published in The Free Press Journal and Navshakti on May 28, 2017.


This is for your information & records.

Thanking you,

Yours faithfully,
For Advanced Enzyme Technologies Limited



Sanjay Basantani
Company Secretary and Head-Legal



Encl: As above

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetics, 5th Floor, Near UC Service Road, Louiswadi, Thane-400604, Maharashtra, India. Tel No: +91-22-41703200 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id : sanjay@advancedenzymes.com

EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 2017 (₹ in million)

Particulars	Quarter ended		Year ended	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
	(Audited)	(Unaudited)	(Audited)	(Audited)
Total income from operations (net)	866.23	810.22	3,336.45	2,950.51
Net Profit / (Loss) for the period from ordinary activities after tax	199.40	227.31	923.62	767.47
Net Profit / (Loss) for the period after tax (after Extraordinary items)	199.40	227.31	923.62	767.47
Equity Share Capital	223.26	217.86	223.26	217.86
Reserves excluding Revaluation Reserve as per the last audited Balance Sheet			4,331.36	2,563.20
Earnings Per Share before extraordinary items of ₹ 10 each (not annualised)				
Basic	8.94	10.75	40.95	34.85
Diluted	8.94	10.75	40.93	34.85
Earnings Per Share after extraordinary items of ₹ 10 each (not annualised)				
Basic	8.94	10.75	40.95	34.85
Diluted	8.94	10.75	40.93	34.85

Notes:

- (i) The above is an extract of the detailed format of consolidated audited financial results for the quarter and the year ended 31 March 2017 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of quarterly results (standalone and consolidated) for the quarter and year ended 31st March 2017 are available on the Stock Exchange's website: www.bseindia.com and www.nseindia.com and on Company's website: www.advancedenzymes.com
- (ii) The above financial results of the Company were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 27th May 2017.
- (iii) During the quarter ended 30 September 2016, the Company completed the Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs. 10 each at an issue price of Rs. 896 per Equity share (Rs. 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) via ADVENZYMES and on BSE Limited (BSE) via ADVENZYMES on 1st August 2016. Accordingly, the consolidated unaudited financial results for the quarter ended 31st March 2016 were not subjected to audit or review by the predecessor auditors of the Company and are as prepared by the Holding Company's Management.
- (iv) The proceeds from the IPO of Rs. 499.99 million (including issue related expenses, inclusive of service tax amounting to Rs. 29.32 million).

Details of utilisation of IPO proceeds are as follows:

Particulars	₹ In million	
	As per prospectus	utilised upto 31 March 2017
Investment in Advanced Enzymes USA, Inc., the wholly owned subsidiary for repayment / pre-payment of certain loans availed by Advanced Enzymes USA, Inc.	400.00	400.00
General corporate purposes	71.98	70.67
Share issue expenses	28.01	29.32
Total	499.99	499.99

- (v) The Company has incurred Rs. 210.79 million (inclusive of service tax) as IPO expenses. Of the above IPO expenses certain expenses (such as legal counsel cost, listing fees and other cost) aggregating to Rs. 3.84 million are directly attributable to the Company. Remaining IPO expenses aggregating to Rs. 206.95 million, have been allocated between the Company Rs. 25.48 million and selling shareholders Rs. 181.47 million in proportion to the Equity shares allotted to the public as fresh issue by the Company and under Offer for Sale by the selling shareholders. The total amount attributable to the Company have been adjusted towards the securities premium account.
- (vi) The Shareholders vide a special resolution has approved sub division of shares of the Company in the ratio of 5 shares of face value of Rs. 2 each for every existing 1 share of the face value of Rs. 10 each through postal ballot. The requisite approvals for modification of the Memorandum and Articles of Association of the Company had been accorded by the shareholders on 4th May 2017.
- (vii) The Company has granted 44,000 options under Employee stock option scheme 2015 on 15th February 2017, approved by the nomination and remuneration committee of the Board.
- (viii) The key standalone financial information are as under:

Particulars	Quarter ended		Year ended	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
	(Audited)	(Unaudited)	(Audited)	(Audited)
Total income from operations (net)	560.42	365.09	1,799.22	1,400.69
Profit before tax	144.89	77.83	421.01	254.89
Profit after tax	125.08	67.42	335.32	208.94

By Order of the Board
For Advanced Enzyme Technologies Limited

Sd/-

S.C. Rathil

Whole-time Director

DIN : 00365617

Place : Thane
Date : 27 May 2017

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi,
Thane-400604, Maharashtra, India. Tel No: +91-22-41703200 Fax No: +91-22-25835159
Website: www.advancedenzymes.com, Email Id : sanjay@advancedenzymes.com

**EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR
QUARTER AND YEAR ENDED MARCH 31, 2017** (₹ in million)

Particulars	Quarter ended		Year ended	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
	(Audited)	(Unaudited)	(Audited)	(Audited)
Total income from operations (net)	866.23	810.22	3,336.45	2,950.51
Net Profit / (Loss) for the period from ordinary activities after tax	199.40	227.31	923.62	767.47
Net Profit / (Loss) for the period after tax (after Extraordinary items)	199.40	227.31	923.62	767.47
Equity Share Capital	223.26	217.66	223.26	217.66
Reserves excluding Revaluation Reserve as per the last audited Balance Sheet	-	-	4,331.36	2,563.20
Earnings Per Share before extraordinary items of ₹ 10 each (not annualised)				
Basic	8.94	10.75	40.95	34.85
Diluted	8.94	10.75	40.93	34.85
Earnings Per Share after extraordinary items of ₹ 10 each (not annualised)				
Basic	8.94	10.75	40.95	34.85
Diluted	8.94	10.75	40.93	34.85

Notes:

(i) The above is an extract of the detailed format of consolidated audited financial results for the quarter and the year ended 31 March 2017 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of quarterly results (standalone and consolidated) for the quarter and year ended 31st March 2017 are available on the Stock Exchange's website: www.bseindia.com and www.nseindia.com and on Company's website: www.advancedenzymes.com

(ii) The above financial results of the Company were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 27th May 2017.

(iii) During the quarter ended 30 September 2016, the Company completed the Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs. 10 each at an issue price of Rs. 896 per Equity share (Rs. 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) via idADVENZYMES and on BSE Limited (BSE) via Id 540025 on 1st August 2016. Accordingly, the consolidated unaudited financial results for the quarter ended 31st March 2016 were not subjected to audit or review by the predecessor auditors of the Company and are as prepared by the Holding Company's Management.

(iv) The proceeds from the IPO of Rs. 499.99 million (including issue related expenses, inclusive of service tax amounting to Rs. 29.32 million).

Details of utilisation of IPO proceeds are as follows:

Particulars	As per prospectus	₹ in million	
		utilised upto 31 March 2017	unutilised amount as at 31 March 2017
Investment in Advanced Enzymes USA, Inc., the wholly owned subsidiary for repayment / pre-payment of certain loans availed by Advanced Enzymes USA, Inc.	400.00	400.00	-
General corporate purposes	71.98	70.67	1.31
Share issue expenses	28.01	29.32	(1.31)
Total	499.99	499.99	-

(v) The Company has incurred Rs. 210.79 million (inclusive of service tax) as IPO expenses. Of the above IPO expenses certain expenses (such as legal counsel cost, listing fees and other cost) aggregating to Rs. 3.84 million are directly attributable to the Company. Remaining IPO expenses aggregating to Rs. 206.95 million, have been allocated between the Company Rs. 25.48 million and selling shareholders Rs. 181.47 million in proportion to the Equity shares allotted to the public as fresh issue by the Company and under Offer for Sale by the selling shareholders. The total amount attributable to the Company have been adjusted towards the securities premium account.

(vi) The Shareholders vide a special resolution has approved sub division of shares of the Company in the ratio of 5 shares of face value of Rs. 2 each for every existing 1 share of the face value of Rs. 10 each through postal ballot. The requisite approvals for modification of the Memorandum and Articles of Association of the Company had been accorded by the shareholders on 4th May 2017.

(vii) The Company has granted 44,000 options under Employee stock option scheme 2015 on 15th February 2017, approved by the nomination and remuneration committee of the Board.

(viii) The key standalone financial information are as under.

Particulars	Quarter ended		Year ended	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
	(Audited)	(Unaudited)	(Audited)	(Audited)
Total income from operations (net)	560.42	365.09	1,799.22	1,400.69
Profit before tax	144.89	77.83	421.01	254.89
Profit after tax	125.08	67.42	335.32	208.94

By Order of the Board
For Advanced Enzyme Technologies Limited

Sd/-

S.C. Rathi

Whole-time Director

DIN : 00365617

Place : Thane

Date : 27 May 2017